
Satsuma Pharmaceuticals
Developing best-in-class products to address the unmet needs of migraine sufferers.
Market cap
$36.5m
Enterprise value
($5m)
Share price
$1.10 STSA
Authorizing premium user...
Developing best-in-class products to address the unmet needs of migraine sufferers.